InvestorsHub Logo
Followers 19
Posts 1991
Boards Moderated 0
Alias Born 02/25/2017

Re: Deal McMogulson post# 53063

Tuesday, 04/18/2017 11:04:33 AM

Tuesday, April 18, 2017 11:04:33 AM

Post# of 106839
Additionally, the FDA needs to see that usrm has the financial means to accommodate an RMAT designation and reactivated phase 2/3 trial.

In steps GACP with $5 million on hand.

Ball is now in the fda's court